FDA PCAC meeting scheduled for selected peptide bulk substances

Related peptide pages

BPC-157

A heavily promoted repair and gut peptide where human evidence is still limited to a few narrow sources and FDA-flagged compounding concerns.

preclinical

KPV

A short alpha-MSH-derived peptide motif with preclinical gut-inflammation, delivery, and antimicrobial literature, but no direct human KPV efficacy evidence found.

unclear

TB-500

A recovery-focused peptide name where the first question is whether the source means the TB-500 fragment, full-length thymosin beta-4, or a market vial.

limited-human

MOTS-c

A mitochondrial-derived peptide with human biomarker and association data, preclinical metabolic mechanism work, and no posted intervention results yet.

limited-human

DSIP

A sleep-associated nonapeptide with older human insomnia studies, unresolved biology, and modern emideltide/DSIP claims that need careful source-by-source reading.

limited-human

A neuropeptide analog discussed for stroke, optic nerve disease, focus, mood, stress, and route choice, with mostly intranasal CNS-oriented published evidence and a weaker subcutaneous route narrative from clinic and anecdotal contexts.

preclinical

Epitalon

A short AEDG tetrapeptide discussed in circadian, melatonin, telomere, retina, and longevity contexts, where public claims often exceed direct clinical evidence.

Primary source

Open source page

References

1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.

FDA PCAC meeting scheduled for selected peptide bulk substances

Related peptide pages

BPC-157

KPV

TB-500

MOTS-c

DSIP

Semax

Epitalon

Primary source

References